Literature DB >> 19003025

Transcriptional regulation of indoleamine 2,3-dioxygenase (IDO) by tryptophan and its analogue : Down-regulation of the indoleamine 2,3-dioxygenase (IDO) transcription by tryptophan and its analogue.

Takeaki Okamoto1, Shigenobu Toné, Hiroaki Kanouchi, Chie Miyawaki, Sayuri Ono, Yohsuke Minatogawa.   

Abstract

Indoleamine 2,3-dioxygenase (IDO; EC 1.13.11.42) is a rate-limiting enzyme involved in the catabolism of tryptophan, which is an essential amino acid. It is induced under pathological conditions, such as the presence of viral infections or tumour cells. This enzyme is induced by IFN-gamma in the mouse rectal carcinoma cell line CMT-93. It is known that both 1-methyl-L: -tryptophan (1-MT) and methylthiohydantoin-DL: -tryptophan (MTH-trp) are tryptophan analogues, and are authentic inhibitors of the enzymatic activity of IDO. In this study, we examined the effects of both 1-MT and MTH-trp on the IFN-gamma inducible IDO expression of CMT-93. As a result, the IFN-gamma inducible IDO mRNA and the protein levels in CMT-93 were suppressed by 1-MT and MTH-trp, independently. Moreover, tryptophan (Trp), as a substrate of IDO, also suppressed IDO induction by IFN-gamma at the transcriptional level. These results suggest that 1-MT and MTH-trp are as inhibitors of IDO enzymatic activity, and Trp suppresses IDO induction by IFN-gamma at the transcriptional level.

Entities:  

Year:  2007        PMID: 19003025      PMCID: PMC2267499          DOI: 10.1007/s10616-007-9081-4

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  19 in total

1.  Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR.

Authors:  L Overbergh; D Valckx; M Waer; C Mathieu
Journal:  Cytokine       Date:  1999-04       Impact factor: 3.861

2.  Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

Authors:  Alexander J Muller; James B DuHadaway; P Scott Donover; Erika Sutanto-Ward; George C Prendergast
Journal:  Nat Med       Date:  2005-02-13       Impact factor: 53.440

3.  Indoleamine 2,3-dioxygenase. Purification and some properties.

Authors:  T Shimizu; S Nomiyama; F Hirata; O Hayaishi
Journal:  J Biol Chem       Date:  1978-07-10       Impact factor: 5.157

4.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

5.  Human macrophages degrade tryptophan upon induction by interferon-gamma.

Authors:  E R Werner; G Bitterlich; D Fuchs; A Hausen; G Reibnegger; G Szabo; M P Dierich; H Wachter
Journal:  Life Sci       Date:  1987-07-20       Impact factor: 5.037

Review 6.  Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism.

Authors:  M W Taylor; G S Feng
Journal:  FASEB J       Date:  1991-08       Impact factor: 5.191

Review 7.  IDO expression by dendritic cells: tolerance and tryptophan catabolism.

Authors:  Andrew L Mellor; David H Munn
Journal:  Nat Rev Immunol       Date:  2004-10       Impact factor: 53.106

8.  Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase.

Authors:  O Takikawa; R Yoshida; R Kido; O Hayaishi
Journal:  J Biol Chem       Date:  1986-03-15       Impact factor: 5.157

9.  Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity.

Authors:  O Takikawa; T Kuroiwa; F Yamazaki; R Kido
Journal:  J Biol Chem       Date:  1988-02-05       Impact factor: 5.157

10.  Inhibition of T cell proliferation by macrophage tryptophan catabolism.

Authors:  D H Munn; E Shafizadeh; J T Attwood; I Bondarev; A Pashine; A L Mellor
Journal:  J Exp Med       Date:  1999-05-03       Impact factor: 14.307

View more
  13 in total

Review 1.  Trial watch: IDO inhibitors in cancer therapy.

Authors:  Erika Vacchelli; Fernando Aranda; Alexander Eggermont; Catherine Sautès-Fridman; Eric Tartour; Eugene P Kennedy; Michael Platten; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-15       Impact factor: 8.110

2.  Novel 1-alkyl-tryptophan derivatives downregulate IDO1 and IDO2 mRNA expression induced by interferon-gamma in dendritic cells.

Authors:  Ting Sun; Xiang-Hua Chen; Zheng-De Tang; Jiong Cai; Xiao-Yan Wang; Shih-Chen Wang; Zhao-Long Li
Journal:  Mol Cell Biochem       Date:  2010-04-28       Impact factor: 3.396

3.  Indolamine 2,3-dioxygenase expression by monocytes and dendritic cell populations in hepatitis C patients.

Authors:  S Schulz; A Landi; R Garg; J A Wilson; S van Drunen Littel-van den Hurk
Journal:  Clin Exp Immunol       Date:  2015-06       Impact factor: 4.330

4.  Soluble CD83 ameliorates experimental colitis in mice.

Authors:  J Eckhardt; S Kreiser; M Döbbeler; C Nicolette; M A DeBenedette; I Y Tcherepanova; C Ostalecki; A J Pommer; C Becker; C Günther; E Zinser; T W Mak; A Steinkasserer; M Lechmann
Journal:  Mucosal Immunol       Date:  2014-01-15       Impact factor: 7.313

5.  Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma.

Authors:  Hiroshi Urakawa; Yoshihiro Nishida; Hiroatsu Nakashima; Yoshie Shimoyama; Shigeo Nakamura; Naoki Ishiguro
Journal:  Clin Exp Metastasis       Date:  2009-10-06       Impact factor: 5.150

Review 6.  Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?

Authors:  Stefan Löb; Alfred Königsrainer; Hans-Georg Rammensee; Gerhard Opelz; Peter Terness
Journal:  Nat Rev Cancer       Date:  2009-06       Impact factor: 60.716

7.  Influence of tryptophan contained in 1-Methyl-Tryptophan on antimicrobial and immunoregulatory functions of indoleamine 2,3-dioxygenase.

Authors:  Silvia K Schmidt; Stephan Siepmann; Katja Kuhlmann; Helmut E Meyer; Sabine Metzger; Sabine Pudelko; Margret Leineweber; Walter Däubener
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

8.  The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells.

Authors:  Christiane A Opitz; Ulrike M Litzenburger; Uta Opitz; Felix Sahm; Katharina Ochs; Christian Lutz; Wolfgang Wick; Michael Platten
Journal:  PLoS One       Date:  2011-05-20       Impact factor: 3.240

Review 9.  Targeting the indoleamine 2,3-dioxygenase pathway in cancer.

Authors:  Yong Wha Moon; Joud Hajjar; Patrick Hwu; Aung Naing
Journal:  J Immunother Cancer       Date:  2015-12-15       Impact factor: 13.751

10.  Endothelial indoleamine 2,3-dioxygenase-1 regulates the placental vascular tone and is deficient in intrauterine growth restriction and pre-eclampsia.

Authors:  Pablo Zardoya-Laguardia; Astrid Blaschitz; Birgit Hirschmugl; Ingrid Lang; Sereina A Herzog; Liudmila Nikitina; Martin Gauster; Martin Häusler; Mila Cervar-Zivkovic; Eva Karpf; Ghassan J Maghzal; Chris P Stanley; Roland Stocker; Christian Wadsack; Saša Frank; Peter Sedlmayr
Journal:  Sci Rep       Date:  2018-04-03       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.